Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NovoCure LtdNVCR · Entity 4494 | Director | June 03, 2026 | June 05, 2026 |
| PERNIX THERAPEUTICS HOLDINGS, INC.PTX · Entity 161208 | Director | May 22, 2018 | May 23, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NovoCure Ltd
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 101,109 |
Reported balance
After 2026-06-03 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 11,610 · Balance 101,109 F1: Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.15 · Expires 2036-06-03 | Direct | 16,999 |
Reported balance
After 2026-06-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-03 · Grant · Acquired 16,999 · Balance 16,999 F2: Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
F2: Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
PERNIX THERAPEUTICS HOLDINGS, INC.
Report date May 22, 2018 · Filed May 23, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.63 · Expires 2028-05-21 | Direct | 25,000 |
Reported balance
After 2018-05-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-05-22 · Grant · Acquired 25,000 · Balance 25,000 F1: The stock option vests in four equal annual installments of 6,250 shares over a four-year period, with the first installment vesting on May 22, 2019, which is the one-year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests in four equal annual installments of 6,250 shares over a four-year period, with the first installment vesting on May 22, 2019, which is the one-year anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 25, 2020 Filed Aug 27, 2020 20:13 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 7,112 | $0.00 Strike: $7.03 | $0.00 |
DisclosureSEC source: 0001645113-20-000122 · wf-form4_159855918511008.xml · derivative · entry 3 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 7,112 shares Expires 2023-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| August 25, 2020 Filed Aug 27, 2020 20:13 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 7,112 | $80.13 | $569,891.67 |
DisclosureSEC source: 0001645113-20-000122 · wf-form4_159855918511008.xml · nonDerivative · entry 2 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,045 F1 · price: On August 25, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung, Mr. Leung sold 7,112 shares in multiple trades at prices ranging from $80.00 to $80.47. The price reported above reflects the weighted average sale price. Mr. Leung hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 25, 2020 Filed Aug 27, 2020 20:13 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 7,112 | $7.03 | $49,997.36 |
DisclosureSEC source: 0001645113-20-000122 · wf-form4_159855918511008.xml · nonDerivative · entry 1 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,157 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 30, 2020 Filed Aug 3, 2020 21:45 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 7,112 | $0.00 Strike: $7.03 | $0.00 |
DisclosureSEC source: 0001645113-20-000112 · wf-form4_159649104514497.xml · derivative · entry 3 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,112 Underlying: Ordinary Shares · 7,112 shares Expires 2023-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| July 30, 2020 Filed Aug 3, 2020 21:45 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 7,112 | $75.00 | $533,400.00 |
DisclosureSEC source: 0001645113-20-000112 · wf-form4_159649104514497.xml · nonDerivative · entry 2 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,045 F1 · price: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung. Read SEC document |
| July 30, 2020 Filed Aug 3, 2020 21:45 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 7,112 | $7.03 | $49,997.36 |
DisclosureSEC source: 0001645113-20-000112 · wf-form4_159649104514497.xml · nonDerivative · entry 1 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,157 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 22, 2020 Filed Jul 23, 2020 23:32 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 9,500 | $0.00 Strike: $7.03 | $0.00 |
DisclosureSEC source: 0001645113-20-000100 · wf-form4_159554712390924.xml · derivative · entry 8 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,214 Underlying: Ordinary Shares · 9,500 shares Expires 2023-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| July 22, 2020 Filed Jul 23, 2020 23:32 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,504 | $67.46 | $303,844.34 |
DisclosureSEC source: 0001645113-20-000100 · wf-form4_159554712390924.xml · nonDerivative · entry 6 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,045 F4 · price: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung, Mr. Leung sold 4,504 shares in multiple trades at prices ranging from $67.21 to $67.85. The price reported above reflects the weighted average sale price. Mr. Leung hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 22, 2020 Filed Jul 23, 2020 23:32 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 4,573 | $66.75 | $305,256.90 |
DisclosureSEC source: 0001645113-20-000100 · wf-form4_159554712390924.xml · nonDerivative · entry 5 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,549 F3 · price: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung, Mr. Leung sold 4,573 shares in multiple trades at prices ranging from $66.21 to $67.19. The price reported above reflects the weighted average sale price. Mr. Leung hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 22, 2020 Filed Jul 23, 2020 23:32 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 423 | $65.48 | $27,695.93 |
DisclosureSEC source: 0001645113-20-000100 · wf-form4_159554712390924.xml · nonDerivative · entry 4 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,122 F2 · price: On July 22, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung, Mr. Leung sold 423 shares in multiple trades at prices ranging from $65.02 to $65.80. The price reported above reflects the weighted average sale price. Mr. Leung hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 22, 2020 Filed Jul 23, 2020 23:32 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 9,500 | $7.03 | $66,785.00 |
DisclosureSEC source: 0001645113-20-000100 · wf-form4_159554712390924.xml · nonDerivative · entry 3 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,545 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 23:32 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 500 | $0.00 Strike: $7.03 | $0.00 |
DisclosureSEC source: 0001645113-20-000100 · wf-form4_159554712390924.xml · derivative · entry 7 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,714 Underlying: Ordinary Shares · 500 shares Expires 2023-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 23:32 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 500 | $65.07 | $32,536.50 |
DisclosureSEC source: 0001645113-20-000100 · wf-form4_159554712390924.xml · nonDerivative · entry 2 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,045 F1 · price: On July 21, 2020, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung, Mr. Leung sold 500 shares in multiple trades at prices ranging from $65.00 to $65.22. The price reported above reflects the weighted average sale price. Mr. Leung hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 21, 2020 Filed Jul 23, 2020 23:32 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 500 | $7.03 | $3,515.00 |
DisclosureSEC source: 0001645113-20-000100 · wf-form4_159554712390924.xml · nonDerivative · entry 1 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,545 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 22:14 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantOptions to Buy Ordinary Shares · Derivative | 5,101 | $0.00 Strike: $67.89 | $0.00 |
DisclosureSEC source: 0001645113-20-000091 · wf-form4_159200002154383.xml · derivative · entry 2 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,101 Underlying: Ordinary Shares · 5,101 shares Expires 2030-06-10 F2 · derivative.exercise_date: Options to buy 5,101 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2021 annual general meeting of shareholders. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 22:14 UTC | NovoCure Ltd NVCR · Entity 4494 | GrantRestricted Stock Units | 2,541 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-20-000091 · wf-form4_159200002154383.xml · nonDerivative · entry 1 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,045 F1 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (1) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2021 annual general meeting of shareholders. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:23 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 20,000 | $0.00 Strike: $7.03 | $0.00 |
DisclosureSEC source: 0001645113-19-000013 · wf-form4_157480339566895.xml · derivative · entry 3 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,214 Underlying: Ordinary Shares · 20,000 shares Expires 2023-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:23 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 20,000 | $95.00 | $1,900,000.00 |
DisclosureSEC source: 0001645113-19-000013 · wf-form4_157480339566895.xml · nonDerivative · entry 2 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,504 F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 21:23 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 20,000 | $7.03 | $140,600.00 |
DisclosureSEC source: 0001645113-19-000013 · wf-form4_157480339566895.xml · nonDerivative · entry 1 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 21:27 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 20,000 | $0.00 Strike: $7.03 | $0.00 |
DisclosureSEC source: 0001645113-19-000012 · wf-form4_157445803633924.xml · derivative · entry 3 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,214 Underlying: Ordinary Shares · 20,000 shares Expires 2023-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 21:27 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 20,000 | $90.00 | $1,800,000.00 |
DisclosureSEC source: 0001645113-19-000012 · wf-form4_157445803633924.xml · nonDerivative · entry 2 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,504 F1 · price: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 21:27 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 20,000 | $7.03 | $140,600.00 |
DisclosureSEC source: 0001645113-19-000012 · wf-form4_157445803633924.xml · nonDerivative · entry 1 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 21:24 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 10,000 | $0.00 Strike: $7.03 | $0.00 |
DisclosureSEC source: 0001645113-19-000010 · wf-form4_157419864521327.xml · derivative · entry 13 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,214 Underlying: Ordinary Shares · 10,000 shares Expires 2023-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 21:24 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 10,000 | $85.00 | $850,000.00 |
DisclosureSEC source: 0001645113-19-000010 · wf-form4_157419864521327.xml · nonDerivative · entry 10 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,504 Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 21:24 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 10,000 | $7.03 | $70,300.00 |
DisclosureSEC source: 0001645113-19-000010 · wf-form4_157419864521327.xml · nonDerivative · entry 9 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:24 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 5,257 | $0.00 Strike: $7.03 | $0.00 |
DisclosureSEC source: 0001645113-19-000010 · wf-form4_157419864521327.xml · derivative · entry 12 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,214 Underlying: Ordinary Shares · 5,257 shares Expires 2023-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:24 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 4,743 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001645113-19-000010 · wf-form4_157419864521327.xml · derivative · entry 11 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,743 shares Expires 2021-09-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:24 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 354 | $84.00 | $29,737.42 |
DisclosureSEC source: 0001645113-19-000010 · wf-form4_157419864521327.xml · nonDerivative · entry 8 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,504 F7 · price: On November 15, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung, Mr. Leung sold 354 shares in multiple trades at prices ranging from $84.00 to $84.01. The price reported above reflects the weighted average sale price. Mr. Leung hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:24 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 3,203 | $83.51 | $267,485.73 |
DisclosureSEC source: 0001645113-19-000010 · wf-form4_157419864521327.xml · nonDerivative · entry 7 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,858 F6 · price: On November 15, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung, Mr. Leung sold 3,203 shares in multiple trades at prices ranging from $82.99 to $83.94. The price reported above reflects the weighted average sale price. Mr. Leung hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:24 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,700 | $82.52 | $140,282.30 |
DisclosureSEC source: 0001645113-19-000010 · wf-form4_157419864521327.xml · nonDerivative · entry 6 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,061 F5 · price: On November 15, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung, Mr. Leung sold 1,700 shares in multiple trades at prices ranging from $81.98 to $82.91. The price reported above reflects the weighted average sale price. Mr. Leung hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:24 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 5,257 | $7.03 | $36,956.71 |
DisclosureSEC source: 0001645113-19-000010 · wf-form4_157419864521327.xml · nonDerivative · entry 5 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,761 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:24 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 443 | $84.02 | $37,220.42 |
DisclosureSEC source: 0001645113-19-000010 · wf-form4_157419864521327.xml · nonDerivative · entry 4 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,504 F4 · price: On November 15, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung, Mr. Leung sold 443 shares in multiple trades at prices ranging from $84.00 to $84.05. The price reported above reflects the weighted average sale price. Mr. Leung hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:24 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 2,800 | $83.50 | $233,802.80 |
DisclosureSEC source: 0001645113-19-000010 · wf-form4_157419864521327.xml · nonDerivative · entry 3 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,947 F3 · price: On November 15, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung, Mr. Leung sold 2,800 shares in multiple trades at prices ranging from $82.98 to $83.94. The price reported above reflects the weighted average sale price. Mr. Leung hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:24 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 1,500 | $82.55 | $123,825.00 |
DisclosureSEC source: 0001645113-19-000010 · wf-form4_157419864521327.xml · nonDerivative · entry 2 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,747 F2 · price: On November 15, 2019, pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung, Mr. Leung sold 1,500 shares in multiple trades at prices ranging from $81.98 to $82.92. The price reported above reflects the weighted average sale price. Mr. Leung hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:24 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 4,743 | $3.44 | $16,315.92 |
DisclosureSEC source: 0001645113-19-000010 · wf-form4_157419864521327.xml · nonDerivative · entry 1 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,247 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung. Read SEC document |
| November 11, 2019 Filed Nov 13, 2019 21:33 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 5,000 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001645113-19-000006 · wf-form4_157368078179147.xml · derivative · entry 3 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,743 Underlying: Ordinary Shares · 5,000 shares Expires 2021-09-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| November 11, 2019 Filed Nov 13, 2019 21:33 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 5,000 | $79.57 | $397,850.00 |
DisclosureSEC source: 0001645113-19-000006 · wf-form4_157368078179147.xml · nonDerivative · entry 2 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,504 F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung. Read SEC document |
| November 11, 2019 Filed Nov 13, 2019 21:33 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 5,000 | $3.44 | $17,200.00 |
DisclosureSEC source: 0001645113-19-000006 · wf-form4_157368078179147.xml · nonDerivative · entry 1 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 10, 2019 Filed Oct 15, 2019 20:12 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 5,000 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001628280-19-012287 · wf-form4_157117031324448.xml · derivative · entry 3 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,743 Underlying: Ordinary Shares · 5,000 shares Expires 2021-09-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| October 10, 2019 Filed Oct 15, 2019 20:12 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 5,000 | $72.28 | $361,400.00 |
DisclosureSEC source: 0001628280-19-012287 · wf-form4_157117031324448.xml · nonDerivative · entry 2 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,504 F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung. Read SEC document |
| October 10, 2019 Filed Oct 15, 2019 20:12 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 5,000 | $3.44 | $17,200.00 |
DisclosureSEC source: 0001628280-19-012287 · wf-form4_157117031324448.xml · nonDerivative · entry 1 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 20:04 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 5,000 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001209191-19-049286 · doc4.xml · derivative · entry 3 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,743 Underlying: Ordinary Shares · 5,000 shares Expires 2021-09-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 20:04 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 5,000 | $76.63 | $383,150.00 |
DisclosureSEC source: 0001209191-19-049286 · doc4.xml · nonDerivative · entry 2 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,504 F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung. Read SEC document |
| September 10, 2019 Filed Sep 12, 2019 20:04 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 5,000 | $3.44 | $17,200.00 |
DisclosureSEC source: 0001209191-19-049286 · doc4.xml · nonDerivative · entry 1 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 20:18 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 5,000 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001209191-19-045896 · doc4.xml · derivative · entry 3 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,743 Underlying: Ordinary Shares · 5,000 shares Expires 2021-09-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 20:18 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 5,000 | $86.45 | $432,250.00 |
DisclosureSEC source: 0001209191-19-045896 · doc4.xml · nonDerivative · entry 2 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,504 F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 20:18 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 5,000 | $3.44 | $17,200.00 |
DisclosureSEC source: 0001209191-19-045896 · doc4.xml · nonDerivative · entry 1 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung. Read SEC document |
| July 10, 2019 Filed Jul 12, 2019 20:04 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOptions to Buy Ordinary Shares · Derivative | 5,000 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0001209191-19-041912 · doc4.xml · derivative · entry 3 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,743 Underlying: Ordinary Shares · 5,000 shares Expires 2021-09-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested as of the date hereof. Read SEC document |
| July 10, 2019 Filed Jul 12, 2019 20:04 UTC | NovoCure Ltd NVCR · Entity 4494 | SaleOrdinary Shares | 5,000 | $64.83 | $324,155.00 |
DisclosureSEC source: 0001209191-19-041912 · doc4.xml · nonDerivative · entry 2 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,504 F2 · price: On July 10, 2019, Mr. Leung sold 5,000 shares in multiple trades at prices ranging from $64.62 to $65.39. The price reported above reflects the weighted average sale price. Mr. Leung hereby undertakes to provide to the Staff, the issuer or any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 10, 2019 Filed Jul 12, 2019 20:04 UTC | NovoCure Ltd NVCR · Entity 4494 | Exercise / conversionOrdinary Shares | 5,000 | $3.44 | $17,200.00 |
DisclosureSEC source: 0001209191-19-041912 · doc4.xml · nonDerivative · entry 1 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leung. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.